Purchase this article with an account.
Alfredo Ruggeri, Alexandra Trivli, Georgios Dalianis, Chryssa Terzidou; Improvement in mixed-type dry eye patients after treatment with the QMR®-based electrotherapy device Rexon-Eye®. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1238.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We investigated the efficacy of the low-power, high-frequency electrical current treatment administered by Rexon-Eye® in a cohort of 18 patients affected by mixed-type dry eye disease (DED) of medium to severe level.
18 mixed type DED patients (17 female and 1 male; age range 42-81 years) were randomly recruited and treated. Therapy was administered with the Rexon-Eye® device (Resono Ophthalmic, Sandrigo, Italy), which applies, via an electrode mask worn over closed eyes, a weak alternate electrical current with a specific spectrum of frequencies (4-64 MHz, Quantum Molecular Resonance, QMR®). The treatment protocol provides for one 20-min session per week, for 4 weeks. Patients were examined at baseline and one month after the last treatment, by measuring: tear meniscus height (TMH), non-invasive tear break-up time (NIBUT), measured with IDRA (SBM Sistemi, Turin, Italy); Meibomian gland number (in lower eyelid) and quality of secretion; Ocular Surface Disease Index (OSDI) score; Schirmer’s II test; ocular inflammation, by Oxford staining and by MMP9 (with InflammaDry by Quidel, San Diego (CA), USA).
Results are reported in Table 1 and 2. In this cohort of patients, all clinical endpoints markedly improved, with a limited improvement only in the Schirmer’s II test. Clinical parameters related to inflammation especially showed a remarkable benefit, as evidenced by the reduction of MMP9 and Oxford staining and normalization of TMH. Subjective benefit (OSDI) was reported by patients and no adverse event was observed in any of them.
In accordance with previous studies, Rexon-Eye® proved to be very effective in improving subjective and objective ocular parameters. Of particular interest in this mixed-type DED patients cohort is the capability of Rexon-Eye® to normalize the clinical parameters affected by inflammation.
This is a 2021 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only